Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis

European Respiratory Journal

Volumn 49, Issue 5, 2017, Pages

  Olaru, Ioana D ^a,b   Heyckendorf, Jan ^a,c   Andres, Sönke ^a   Kalsdorf, Barbara ^a,c   Lange, Christoph ^a,c,d,e  

^a RESEARCH CENTER BORSTEL   (Germany)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^c German Center for Infection Research (DZIF) Clinical Tuberculosis Unit   (Germany)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIVERSITY OF NAMIBIA   (Namibia)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; FEMALE; HUMAN; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; YOUNG ADULT;

ADULT; ANTITUBERCULAR AGENTS; DIARYLQUINOLINES; FEMALE; HUMANS; MALE; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 85035061995     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00742-2017     Document Type: Letter

References (18)

1. World Health Organization. Global Tuberculosis Report 2016. Geneva, WHO, 2016.
2. Olaru ID, von Groote-Bidlingmaier F, Heyckendorf J, et al. Novel drugs against tuberculosis: a clinician’s perspective. Eur Respir J 2015; 45: 1119–1131.
3. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397–2405.
4. Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723–732.
5. Pym AS, Diacon AH, Tang SJ, et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J 2016; 47: 564–574.
6. World Health Organization. Report of the Guideline Development Group Meeting on the use of bedaquiline in the treatment of multidrug-resistant tuberculosis. A review of available evidence (2016). Geneva, World Health Organization, 2017.
7. Guglielmetti L, Le Dû D, Jachym M, et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis 2015; 60: 188–194.
8. Ndjeka N, Conradie F, Schnippel K, et al. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. Int J Tuberc Lung Dis 2015; 19: 979–985.
9. Skrahina A, Hurevich H, Falzon D, et al. Bedaquiline in the multidrug-resistant tuberculosis treatment: Belarus experience. Int J Mycobacteriol 2016; 5 Suppl 1: S62–SS3.
10. Udwadia ZF, Ganatra S, Mullerpattan JB. Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India. Eur Respir J 2017; 49: 1601699.
11. Bemer P, Palicova F, Rüsch-Gerdes S, et al. Multicenter evaluation of fully automated BACTEC Mycobacteria Growth Indicator Tube 960 system for susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 2002; 40: 150–154.
12. Guglielmetti L, Jaspard M, Le Du D, et al. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. Eur Respir J 2017; 49: 1601799.
13. Mbuagbaw L. Review of available evidence on the use of bedaquiline for the treatment of multidrug-resistant tuberculosis: Data analysis report. Prepared for the World Health Organization, 2017. www.who.int/tb/publications/2017/Appendix_GDGReport_Bedaquiline.pdf Date last updated: March 8, 2017.
14. Hoffmann H, Kohl TA, Hofmann-Thiel S, et al. Delamanid and bedaquiline resistance in Mycobacterium tuberculosis ancestral beijing genotype causing extensively drug-resistant tuberculosis in a tibetan refugee. Am J Respir Crit Care Med 2016; 193: 337–340.
15. Veziris N, Bernard C, Guglielmetti L, et al. Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors. Eur Respir J 2017; 49: 1601719.
16. Wirth D, Dass R, Hettle R. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany. BMC Health Serv Res 2017; 17: 182.
17. Kurbatova EV, Cegielski JP, Lienhardt C, et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respir Med 2016; 3: 201–209.
18. Günther G, Lange C, Alexandru S, et al. Treatment Outcomes in Multidrug-Resistant Tuberculosis. N Engl J Med 2016; 375: 1103–1105.